EP4045088A1 - Method for the preparation of polymeric carriers for ph- controlled drug release and their conjugates with drugs - Google Patents

Method for the preparation of polymeric carriers for ph- controlled drug release and their conjugates with drugs

Info

Publication number
EP4045088A1
EP4045088A1 EP20810857.1A EP20810857A EP4045088A1 EP 4045088 A1 EP4045088 A1 EP 4045088A1 EP 20810857 A EP20810857 A EP 20810857A EP 4045088 A1 EP4045088 A1 EP 4045088A1
Authority
EP
European Patent Office
Prior art keywords
group
drug
statistical copolymer
general formula
linear statistical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20810857.1A
Other languages
German (de)
English (en)
French (fr)
Inventor
Petr Chytil
Eva RANDAROVA
Tomas Etrych
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ustav Makromolekularni Chemie Av Cr V V I
Ustav Makromolekularni Chemie Av Cr VVI
Original Assignee
Ustav Makromolekularni Chemie Av Cr V V I
Ustav Makromolekularni Chemie Av Cr VVI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ustav Makromolekularni Chemie Av Cr V V I, Ustav Makromolekularni Chemie Av Cr VVI filed Critical Ustav Makromolekularni Chemie Av Cr V V I
Publication of EP4045088A1 publication Critical patent/EP4045088A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F20/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
    • C08F20/02—Monocarboxylic acids having less than ten carbon atoms, Derivatives thereof
    • C08F20/52—Amides or imides
    • C08F20/54—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide
    • C08F20/58—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide containing oxygen in addition to the carbonamido oxygen, e.g. N-methylolacrylamide, N-acryloylmorpholine
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F20/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
    • C08F20/02—Monocarboxylic acids having less than ten carbon atoms, Derivatives thereof
    • C08F20/52—Amides or imides
    • C08F20/54—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide
    • C08F20/60—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide containing nitrogen in addition to the carbonamido nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/52—Amides or imides
    • C08F220/54—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide
    • C08F220/58—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide containing oxygen in addition to the carbonamido oxygen, e.g. N-methylolacrylamide, N-(meth)acryloylmorpholine
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/52—Amides or imides
    • C08F220/54—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide
    • C08F220/60—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide containing nitrogen in addition to the carbonamido nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C08F8/30—Introducing nitrogen atoms or nitrogen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F2438/00—Living radical polymerisation
    • C08F2438/03—Use of a di- or tri-thiocarbonylthio compound, e.g. di- or tri-thioester, di- or tri-thiocarbamate, or a xanthate as chain transfer agent, e.g . Reversible Addition Fragmentation chain Transfer [RAFT] or Macromolecular Design via Interchange of Xanthates [MADIX]

Definitions

  • An important feature of these transport systems is the large size in the aqueous environment, which can ensure preferential deposition of the drug delivery system in the tumour tissue of a number of solid tumours (the so-called EPR effect) and in inflammatory tissue (the so-called ELVIS effect).
  • the release of the active drug from the delivery system can advantageously be achieved via a biodegradable linker used to bind the drug to a polymer, the degradation of which in the target tissue leads to a targeted and controlled activation of the drug, preferably in this tissue.
  • hydrazide groups need to be protected during polymerisation.
  • the authors of the publication therefore applied protection with a tert- butoxycarbonyl (Boc) group.
  • the dithiobenzoate groups at the end of the polymeric carrier were removed by reduction with sodium borohydride and the resulting -SH groups were blocked by reaction with N- ethylmaleimide. Only then were the Boc groups removed with trifluoro acetic acid (TFA).
  • TFA trifluoro acetic acid
  • the disadvantage of this carrier synthesis is the need for several subsequent steps after polymerisation.
  • the step of deprotecting the hydrazide groups is a step which is difficult to reproduce and does not allow easy preparation of larger batches of the polymer required for industrial application.
  • the final purification of the polymer by gel filtration means complications for the preparation of a larger amount of the carrier.
  • the described procedure for the synthesis of the carrier was also used in other publications. The basis is always the copolymerisation of HPMA with a monomer bearing Boc protected hydrazide groups (e.g. Subr V. et al. Biomacromolecules 2014, 15 (8), 3030-3043, Chytil P. et al. Macromol. Biosci. 2015, 15 (6), 839-850, Lomkova E. et al. Biomacromolecules 2016, 17 (11), 3493-3507). The blocking of the end groups and the subsequent deprotection of the hydrazide groups differed slightly.
  • the process should also be easily transferable to an industrial scale.
  • Natural amino acids can be understood as naturally occurring acids: histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine, arginine, cysteine, glutamine, glycine, proline, tyrosine, alanine, aspartic acid, asparagine, glutamic acid, serine, selenocysteine.
  • Their side chains are to be understood as chains attached to the alpha-carbon of a particular amino acid.
  • a semitelechelic linear copolymer is a statistical copolymer formed by a radical polymerisation reaction.
  • the end groups of the resulting linear copolymer contain parts of molecules of the polymerisation initiator (e.g. azo initiators, such as 2,2'-azobis(2-methylpropionitrile) (AIBN), 4,4'-azobis(4-cyanopentanoic acid) (ACVA), 2,2'-azobis(4-methoxy-2,4-dimethylpentanenitrile) (V70)), and of the transfer agent (preferably selected from the group consisting of 2-cyano-2- propyl benzodithioate, 4-cyano-4-(thiobenzoylthio)pentanoic acid, 2-cyano-2-propyldodecyl trithio-carbonate, 2-cyano-2-propylethyltrithiocarbonate and 4-cyano-4-[(dodecylsulphanylthio- carbonyl)sulphanyl]
  • the end groups of the copolymer contain at one end a radical leaving group of the transfer agent, preferably 2-cyano-2-propyl, or 5-carboxy-2-cyano-2-pentyl.
  • X is selected from the group comprising -CH2-, -(CH2)2-, -(CH2)5- ; -C(H)(CH 2 -Phe)-, -C(H)(CH-iPr)-, -C(H)(sec-Bu)-; -CH 2 -C(O)-NH-CH 2 -;
  • the method for the preparation of polymeric carriers of general formula (I) comprises the following steps: a) providing monomers of the polymeric carrier, thus providing HPMA (commercially available) and providing a monomer of general formula (III), wherein X is as defined above, and Y is selected from the group consisting of hydroxyl, (C1-C6) alkoxy, benzoxy, 4-nitrophenoxy, 2,3,4,5,6-pentafluorophenoxy, succinimidyl, (C1-C6) alkylthio group and thiazolidine-2-thione group; preferably Y is selected from the group consisting of methoxy, ethoxy, tert-butoxy, tert- butylthio and thiazolidine-2-thione group; b) radical RAFT polymerisation of monomers of the polymeric carrier from step a); c) introduction of hydrazide groups instead of the substituent Y, while in situ modifying the end groups of the linear statistical copolymer to give
  • Step a) of providing polymeric carrier monomers comprises providing A- (2 - hydroxypropyl) methacrylamide (HPMA) and a monomer of general formula (III).
  • HPMA is commercially available and its synthesis is published (e.g. Chytil P. et al., Eur. J. Pharm. Sci., 2010, 41, 73-81).
  • the step of methacryloylation of a commercially available compound of formula HO-C(O)-X-NH 2 followed by an esterification, thioesterification, or imidation of a carboxyl group may be included, preferably by the carbodiimide method using dicyclohexylcarbodiimide, diisopropylcarbodiimide, l-ethyl-3-(3-dimethylaminopropyl)carbodiimide, or other reagents using benzotriazol-l-yloxytripyrrolidinophosphonium hexafluorophosphate or (2-(l H- benzotriazol- 1 -yl)- 1 , 1 ,3 ,3-tetramethyluronium hexafluorophosphate.
  • Step b) of polymerisation of monomers of the polymeric carrier lies in the controlled radical RAFT polymerisation of HPMA with a monomer of general formula (III) in a molar ratio of HPMA: monomer of formula (III) in the range of from 99.5:0.5 to 75:25.
  • the synthesis of the polymer precursors is carried out at a molar ratio of initiator : transfer agent in the range of from 1:1 to 1:10.
  • the synthesis of the polymer precursors is carried out at a molar ratio of transfer agent : monomers in the range of from 1:50 to 1:1000.
  • Step c) of introduction of hydrazide groups while modifying the end groups of the polymeric carrier lies in converting the group Y (reactive esters, thioesters and imides) to hydrazide groups (-NH-NH2) and in situ modification (removal) of sulphur-containing end groups of the polymeric carrier originating from the transfer agent.
  • the double bond compounds are preferably selected from the group comprising N- substituted maleimide and S- substituted vinyl sulphone; more preferably selected from the group comprising divinyl sulphone, carboxy-PEG vinyl sulphone, A-cthyl maleimide.
  • step c) may optionally be followed by step d), in which a biologically active molecule may be attached to the R2 group of general formula (I), if R2 is not
  • the bifunctional agent is A- a m i n o c t h y 1 m a 1 c i m i dc trifluoroacetate, or A- (3 - a m i n o p ro p y 1 ) m a 1 c i m i dc trifluoro acetate
  • the bifunctional agent is maleimidopropionic acid, or carboxy-PEG vinyl sulphone
  • ethynyl group the bifunctional agent is /V-propargylmaleimide
  • an azide group the bifunctional agent is azido-PEG-maleimide
  • the biologically active molecule is selected from the group comprising fluorescent labels, chelators for radionuclides, chelators for contrast agents for nuclear magnetic resonance, targeting groups, oligopeptides, oligosaccharides, peptides, scFc fragments, monoclonal antibodies and specific cell-surface receptor ligands.
  • An example of such an addition of a biologically active substance is the reaction of the end amine group with, for example, ester groups of other biologically active substances, which allows a great variability and universal use of the polymer.
  • the biologically active molecule is a fluorescent label, for example fluorescein, Cyanine 5.5, Cyanine 7, Cyanine 7.5, Dyomics-676, Dyomics-676, Alexa fluor-488; chelators for radionuclides, preferably deferoxamine, DOT A, NOT A, tyrosinamide; targeting groups for targeted biodistribution, preferably targeting oligopeptides, especially selected from the group comprising GE-7 (NPVVGYIGERPQYRDL oligopeptide), GE-11 (YHWYGYTPQNVI oligopeptide), RGD (arginylglycylaspartic acid); scFc fragments; and monoclonal antibodies, preferably anti-CD20, anti-CD38, anti-CD19, anti-Her2Neu, anti-GD2.
  • fluorescent label for example fluorescein, Cyanine 5.5, Cyanine 7, Cyanine 7.5, Dyomics-676, Dyomics-676, Alexa fluor-488
  • the method of binding of a particular known biologically active substance to an amino group, carboxyl group, ethynyl group or azide group of the linear statistical copolymer of general formula (I) may be carried out by standard reactions known to those skilled in the art based on standard knowledge in the technical field.
  • deferoxamine can be bound already in step c) using deferoxamine maleimide.
  • Oligopeptides e.g. GE-7, GE-11, RGD, containing an azide group, i.e. oligopeptides terminated with azidopentanoic acid, can be attached by a catalysed click reaction.
  • fluorescent labels or chelators containing an azide group can be attached.
  • any biologically active substance containing a reactive functional group capable of conjugation with an amino group, a carboxyl group, an ethynyl group or an azide group can be attached to the linear statistical copolymer, or the biologically active substance can be converted to a derivative thereof containing this reactive functional group.
  • Another object of the present invention is a method for preparation of a conjugate of the linear statistical copolymer of general formula (I) based on HPMA copolymers, as defined above, with a drug, in particular by means of a pH-sensitive hydrolysable hydrazone bond.
  • This process comprises preparing the polymeric carrier according to steps a) to c) and optionally step d) above, followed by step e) of linking the drug to a structural unit of general formula (II) of the linear statistical copolymer, as defined above, by a hydrazone bond to form a conjugate of the linear statistical copolymer of formula (I) with the drug.
  • the drug is selected from the group comprising anti-tumour drugs, anti-inflammatory drugs or immuno modulators.
  • the drug is selected from the group comprising anthracycline, doxorubicin, dexamethasone, pirarubicin, epirubicin, ritonavir, docetaxel, paclitaxel, larotaxel, or oxo derivatives thereof (containing at least one keto group).
  • the reaction may be carried out in methanol, dimethyl sulphoxide, dimethyl formamide, dried ethanol and dimethyl acetamide.
  • the synthesis of polymer-drug conjugates is based on the previously described method of binding of doxorubicin (Etrych, T., et al., J. Control. Release, 2001. 73(1): p.
  • the initial concentration of the polymeric carrier for reaction with the keto groups of the drug is in the range of from 100 to 190 mg/mL
  • the concentration of the glacial acetic acid is in the range of from 30 to 80 mg/mL
  • the concentration of the drug/drug oxo derivative is in the range of from 1 to 50 mg/mL
  • the initial polymer concentration for reaction with the keto groups of the drug is 170 mg/mL
  • the acetic acid concentration is 55 mg/mL
  • the drug concentration is 20 mg/mL at 25 °C.
  • the present invention provides a reproducible method for the preparation of very well defined polymeric drug carriers based on HPMA copolymers, allowing the drugs to be bound by a pH-labile hydrazone bond to the carrier.
  • This new method of preparing polymeric carriers by means of controlled polymerisation makes it possible to increase the yields in the polymerisation and, thanks to the advantageous copolymerisation parameters close to one, to control the content of the comonomer unit (according to formula II) in the carrier; the synthesis is significantly easier and cheaper, it allows ‘scale-up’ to large batches and the reproducibility of the synthesis is very good.
  • the biological activity of conjugates of prepared polymeric carriers with drugs is the same as that of conjugates of previously prepared carriers.
  • the prepared copolymers were characterized by determining the weight and number average molar masses (M w , M n ) and the corresponding dispersity index (£ ) ) by gel permeation chromatography (GPC) on a system equipped with a PDA detector (Shimadzu, Japan), RI detector (Optilab REX, Wyatt Technology Corp ., USA) and a multi-angle light scattering detector (DAWN Heleos-II, Wyatt Technology Corp., USA).
  • a TSK 3000 Super SW column was used for SEC and a mixture of methanol (80 %) and 0.3 M acetate buffer pH 6.5 (20 %) as the mobile phase.
  • the sample concentration was 3 mg/mL in all cases.
  • the content of hydrazide groups was determined using the TNBSA test.
  • the content of methyl ester groups and other esters was determined by nuclear magnetic resonance (NMR) on a Bruker Avance III 600 MHz spectrometer in (CD 3 ) 2 SO.
  • the content of bound drugs was determined either spectrophotometrically or by HPLC after total hydrolysis, i.e. release from the polymeric carrier.
  • HPMA was prepared according to the procedure previously described (Chytil P. et al., Eur. J. Pharm. Sci., 2010, 41, 73-82). The product was chromatographically pure.
  • MA-AP-OMe N- methacryloy 1-3 -aminopropionic acid methyl ester
  • Methyl 3-aminopropionate hydrochloride (30 g, 0.215 mol) was dissolved in 350 mL of dichloromethane with vigorous stirring at room temperature. The solution was cooled to 10 - 15 °C and anhydrous sodium carbonate (67 g, 0.645 mol) was added, the temperature was reduced to 5 - 10 °C and then a solution of methacroyl chloride (22.5 g, 0.215 mol (eq.)) in 100 mL of dichloromethane was added dropwise at such a rate that the temperature of the reaction mixture does not exceed 15 °C.
  • MA-AH-OMe was prepared according to the procedure described above using methyl 3- aminohexanoate hydrochloride.
  • the product was chromatographically pure.
  • Example 2a Synthesis of polymer precursor - HPMA copolymer with MA-AH-OMe (poly(HPMA-co-MA-AH-OMe))
  • Poly(HPMA-co-MA-AH-OMe) copolymer was prepared by controlled radical RAFT copolymerisation of HPMA and MA-AH-OMe (prepared according to Example 1) initiated by AIBN in the presence of RAFT transfer agent 2-cyano-2-propyl benzodithioate in a tert-butyl alcohol and dimethyl sulphoxide at 70 °C.
  • HPMA 4.0 g, 27.9 mmol
  • MA-AH-OMe 0.377 g, 1.8 mmol
  • 2-cyano-2-propyl benzodithioate 18.8 mg, 84.9 ⁇ mol
  • AIBN 7.0 mg, 42.5 ⁇ mol
  • the polymerisation mixture was placed in an argon atmosphere in a polymerisation vial (50 mL volume), bubbled with argon for 10 minutes and sealed.
  • the polymerisation vial was placed in a thermostat at 70 °C.
  • the polymerisation mixture was removed from the thermostat after 16 h, cooled in a bath to the room temperature, and the polymer was isolated by precipitation into ethyl acetate (total 800 mL).
  • the precipitated polymer was allowed to settle for about 0.5 h, the solution above the precipitate was sucked off and the polymer was isolated by filtration on a S4 frit.
  • the precipitate was washed with ethyl acetate, transferred to large Petri dishes and dried at room temperature under a diaphragm pump vacuum for about 1 h.
  • the polymer was dissolved in 40 mL of methanol (100 mL Erlenmeyer flask) by means of ultrasound and precipitated into 800 mL of ethyl acetate in the same manner as in the first isolation. After about 0.5 h of sedimentation, the precipitated polymer was isolated by filtration on a S4 frit, washed with ethyl acetate and dried to constant weight (about 5 h) on a diaphragm pump and finally dried under an oil pump vacuum.
  • Copolymers were prepared analogously using other RAFT agents: S-2-cyano-2-propyl-S -ethyl trithiocarbonate, 4-cyano-4-(thiobenzoylthio) pentanoic acid, 2-cyano-2-propyl dodecyl trithiocarbonate, 2-cyano-2-propyl ethyl trithiocarbonate and 4-cyano-4- [(dodecylsulphanyl- thiocarbonyl)sulphanyl] pentanoic acid.
  • Example 2b Synthesis of polymer precursor - HPMA copolymer with MA-AP-OMe (poly(HPMA-co-MA-AP-OMe))
  • the execution and procedure of polymerisation of poly(HPMA-co-MA-AP-OMe) were the same as in Example 2a, the difference being in the composition of the polymerisation mixture.
  • the composition of the polymerisation mixture was as follows: HPMA (4.0 g, 27.9 mmol) and MA- AP-OMe (0.308 g, 1.8 mmol) dissolved in 35.7 mL of tert- butyl alcohol, 2-cyano-2-propyl benzodithioate (18.8 mg, 84.9 ⁇ mol) and AIBN (7.0 mg, 42.5 ⁇ mol) dissolved in 4.0 ml of dimethyl sulphoxide.
  • the polymerisation temperature was 70 °C, the polymerisation time was 16 h.
  • Example 3b Synthesis of polymer precursor poly(HPMA-co-MA-AH-NHNH 2 ) by hydrazinolysis of poly(HPMA-co-MA-AH-MeO) and simultaneous blocking of the end thiol group of the polymer carrier and introduction of fluorescein at the end of the polymer chain
  • Example 3c Synthesis of polymer precursor poly(HPMA-co-MA-AH-NHNH 2 ) by hydrazinolysis of poly(HPMA-co-MA-AH-MeO) and simultaneous blocking of the end thiol group of the polymer carrier and introduction of an amino group at the end of the polymer chain
  • a hydrazide groups-containing copolymer was prepared by hydrazinolysis of a copolymer containing methyl ester groups poly(HPMA-co-MA-AH-OMe) while removing sulphur-containing end groups originating from the transfer agent at the ends of the polymer chains and blocking the resulting end thiol groups by N-aminoethylmaleimide trifluoro acetate.
  • Example 3d Synthesis of diblock polymer precursor poly(HPMA-co-MA-AH-NHNH 2 )-S- S-poly(HPMA-co-MA-AH-NHNH 2 ) by hydrazinolysis of poly(HPMA-co-MA-AH-MeO) and simultaneous mutual reaction of end thiol groups of polymeric carriers wherein
  • Example 2a A solution of poly(HPMA-co-MA-AH-MeO) prepared in Example 2a (500 mg, 0.20 mmol of methyl ester groups) and dithiothreitol (70 mg, 0.45 mmol) in 3.75 mL of dried distilled methanol was bubbled with argon for 5 minutes and then kept under an argon atmosphere. 3.75 mL of hydrazine hydrate (77 mmol) was added to the reaction mixture. The reaction was allowed to proceed for 5 minutes and then precipitated into ethyl acetate to remove dithiothreitol.
  • the precipitated polymer was dissolved in methanol and then the residual hydrazine hydrate together with the solvent was removed on a rotary evaporator under an oil pump vacuum (1 mbar, 1.5 h) to form a diblock copolymer.
  • the product was isolated by precipitation into ethyl acetate (total 200 mL) and then filtered and dried as described above.
  • Example 4 Synthesis of polymer conjugate poly(HPMA-co-MA-AH-NHNH 2 ) with fluorescent label Cyanine 5.5 at the end of the polymer chain
  • the poly(HPMA-co-MA-AH-NHNH 2 ) polymer with end amino groups prepared according to Example 3c was used to bind the fluorescent label Cyanine 5.5 NHS ester.
  • Copolymers with doxorubicin (DOX) attached to a PHPMA carrier by a hydrolytically cleavable hydrazone bond were prepared by reacting copolymers containing hydrazide groups poly(HPMA-co-MA-AH-NHNH 2 ) with doxorubicin hydrochloride (DOX.HC1) in methanol catalysed by acetic acid.
  • DOX doxorubicin
  • Copolymers with dexamethasone attached to a PHPMA carrier by a hydrolytically cleavable hydrazone bond were prepared by reacting hydrazide groups-containing copolymers poly(HPMA-co-MA-AH-NHNH 2 ) with a dexamethasone derivative, dexamethasone oxo -propyl benzoate (DEX), in methanol catalysed by acetic acid.
  • DEX dexamethasone oxo -propyl benzoate
  • the IC50 values are reported in ng doxorubicin/mL and were calculated as the average of several independent assays.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicinal Preparation (AREA)
  • Polymerisation Methods In General (AREA)
EP20810857.1A 2019-10-18 2020-10-16 Method for the preparation of polymeric carriers for ph- controlled drug release and their conjugates with drugs Pending EP4045088A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ2019649A CZ309067B6 (cs) 2019-10-18 2019-10-18 Způsob přípravy polymerních nosičů pro pH-řízené uvolňování léčiv a jejich konjugátů s léčivy
PCT/CZ2020/050080 WO2021073667A1 (en) 2019-10-18 2020-10-16 Method for the preparation of polymeric carriers for ph- controlled drug release and their conjugates with drugs

Publications (1)

Publication Number Publication Date
EP4045088A1 true EP4045088A1 (en) 2022-08-24

Family

ID=73497482

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20810857.1A Pending EP4045088A1 (en) 2019-10-18 2020-10-16 Method for the preparation of polymeric carriers for ph- controlled drug release and their conjugates with drugs

Country Status (3)

Country Link
EP (1) EP4045088A1 (cs)
CZ (1) CZ309067B6 (cs)
WO (1) WO2021073667A1 (cs)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ310444B6 (cs) * 2021-09-13 2025-06-25 Ústav makromolekulární chemie AV ČR, v. v. i. Fluorescenčně značený polymer pro vizualizaci nádorů a jeho použití

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ308419B6 (cs) * 2016-04-11 2020-08-12 Ústav makromolekulární chemie AV ČR, v. v. i. Blokový kopolymer pro překonání lékové rezistence nádorů k chemoterapii, jeho polymerní konjugát s léčivem, farmaceutická kompozice je obsahující, způsob jejich přípravy a jejich použití

Also Published As

Publication number Publication date
CZ309067B6 (cs) 2022-01-12
WO2021073667A1 (en) 2021-04-22
CZ2019649A3 (cs) 2021-04-28

Similar Documents

Publication Publication Date Title
Etrych et al. Biodegradable star HPMA polymer conjugates of doxorubicin for passive tumor targeting
Chytil et al. Properties of HPMA copolymer–doxorubicin conjugates with pH-controlled activation: effect of polymer chain modification
Etrych et al. Conjugates of doxorubicin with graft HPMA copolymers for passive tumor targeting
US6933352B2 (en) Amphiphilic compounds having a dendritic branch structure
EP1503802A2 (en) Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
EP2063914A1 (en) Grafted macromolecular conjugates of doxorubicin with anticancer activity and method of their preparation
Etrych et al. HPMA copolymer conjugates with reduced anti-CD20 antibody for cell-specific drug targeting. I. Synthesis and in vitro evaluation of binding efficacy and cytostatic activity
Tai et al. A novel rapamycin-polymer conjugate based on a new poly (ethylene glycol) multiblock copolymer
EP1689443B1 (en) Polymalic acid-based multifunctional drug delivery system
CN110591079A (zh) 单官能化非线性聚乙二醇的制备方法
AU2017381408A1 (en) Biocompatible and hydrophilic polymer conjugate for targeted delivery of an agent
JP4718117B2 (ja) ターゲット療法用アントラサイクリン系制癌薬のｐＨ感受性重合体コンジュゲート
EP1922087B1 (en) Method for the preparation of polymeric conjugates of doxorubicin with ph-controlled release of the drug
CA2783393C (en) Dendritic high-molecular-weight polymer drug carriers and their conjugates with drugs for treatment of solid tumours
EP4045088A1 (en) Method for the preparation of polymeric carriers for ph- controlled drug release and their conjugates with drugs
WO2005007798A2 (en) Hydroxypropyl methacrylamide polymers and copolymers comprising reactive thiazoline-2-thione
Říhová et al. Doxorubicin release is not a prerequisite for the in vitro cytotoxicity of HPMA-based pharmaceuticals: in vitro effect of extra drug-free GlyPheLeuGly sequences
EP2049157B1 (en) Polymeric conjugates of doxorubicin with ph-regulated release of the drug and a method of preparing
Chytil et al. Structural design and synthesis of polymer prodrugs
Babazadeh et al. Synthesis, characterization and in-vitro evaluation of novel polymeric prodrugs of mefenamic acid
Sintov et al. Polymeric drug delivery of enzymatically degradable pendant agents: Peptidyl-linked procainamide model system studies
WO2021121446A1 (en) Copolymer with hydrolytic release of cancerostatic agent cytarabine, method of its preparation and use thereof
TR2024000271A1 (tr) ß-iyonon yüklü l-arginin peptid dendrimerleri nanopartikül sistemi ve bu sistemin elde edilme yöntemi.
CN115785346A (zh) 含非pH敏感型单体的pH敏感聚合物的合成及应用
Rihova et al. HPMA-Anticancer Drug Conjugates

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220330

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)